RS BioTherapeutics Announces Positive Anti-Inflammatory and Anti-Fibrotic Effects of Lead Compound in Human Lung Tissue

First-in-class, steroid-free compound reduced inflammatory and fibrotic biomarkers in human lung tissue furthering support as a new advancement in the treatment of deadly lung diseasesCUMBERLAND, Md., Jan. 21, 2025 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to develop life-changing medicines for the millions of people suffering from deadly lung diseases characterized by pulmonary inflammation, is pleased to announce that its lead compound (RSBT-001) reduced inflammatory biomarkers and mediator ...